Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: Possible link between endocrinosenescence and immunosenescence

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 6, 1998, Pages 2012-2017

  Straub, R H ^a   Konecna, L ^a   Hrach, S ^a   Rothe, G ^a   Kreutz, M ^a   Scholmerich J ^a   Falk, W ^a   Lang, B ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 6; PRASTERONE; PRASTERONE SULFATE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; B CELL LEUKEMIA; BLOOD LEVEL; FEMALE; HORMONE RELEASE; HUMAN; INFLAMMATORY DISEASE; MALE; MONONUCLEAR CELL; NORMAL HUMAN; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENESCENCE;

EID: 0031732983     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.83.6.4876     Document Type: Article

References (45)

1. De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A. 1994 Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest. 93:2114-2119.
2. Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G. 1992 Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol. 19:22-25.
3. Straub RH, Müller-Ladner U, Lichtinger T, Schölmerich J, Menninger H, Lang B. 1997 Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease modifying antirheumatic drugs. Br J Rheumatol. 36:1298-1303.
4. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. 1993 Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 36:1286-1294.
5. Manolagas SC, Jilka RL. 1995 Bone marrow, cytokines and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 332:305-311.
6. Girasole G, Jilka RL, Passeri G, et al. 1992 17β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest. 89:883-891.
7. Ikeda U, Ikeda M, Seino Y, Takahashi M, Kano S, Shimada K. 1992 Interleukin 6 gene transcripts are expressed in atherosclerotic lesions of genetically hyperlipidemic rabbits. Atherosclerosis. 92:213-218.
8. Loppnow H, Libby P. 1992 Functional significance of human vascular smooth muscle cell-derived interleukin 1 in paracrine and autocrine regulation pathways. Exp Cell Res. 198:283-290.
9. Wood JA, Wood PL, Ryan R, et al. 1993 Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res. 629:245-252.
10. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. 1995 Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett. 202:17-20.
11. Kawano M, Hirano T, Matsuda T, et al. 1988 Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 332:83-85.
12. Greenspan FS. 1991 Basic and clinical endocrinology. East Norwalk: Appleton and Lange; 407-490.
13. Rosenfeld RS, Hellman L, Gallagher TF. 1972 Metabolism and interconversion of dehydroisoandrosterone and dehydroisoandrosterone sulfate. J Clin Endocrinol Metab. 35:187-193.
14. Daynes RA, Araneo BA, Ershler WB, Maloney C, Li G-Z, Ryu S-Y. 1993 Altered regulation of IL-6 production with normal aging: possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J Immunol. 150:5219-5230.
15. Sambrook PN, Eisman JA, Champion GD, Pocock NA. 1988 Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis. Arthritis Rheum. 31:973-978.
16. Deighton CM, Watson MJ, Walker DJ. 1992 Sex hormones in postmenopausal HLA-identical rheumatoid arthritis discordant sibling pairs. J Rheumatol. 19:1663-1667.
17. Lahita RG, Bradlow HL, Ginzler E, Pang S, New M. 1987 Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum. 30:241-248.
18. Straub RH, Zeuner M, Antoniou E, Schölmerich J, Lang B. 1996 Dehydroepiandrosterone sulfate is positively correlated with soluble interleukin 2 receptor and soluble intercellular adhesion molecule in systemic lupus erythematosus. J Rheumatol. 23:856-861.
19. Straub RH, Antoniou E, Zeuner M, Lock G, Schölmerich J, Lang B. 1997 High prolactin and low dehydroepiandrosterone sulfate serum levels in patients with severe systemic sclerosis. Br J Rheumatol. 36:426-432.
20. Andus T, Straub RH, Vogl D, et al. 1996 Low serum levels of dehydroepiandrosterone sulfate (DHEAS) in Crohn's disease (CD) and ulcerative colitis (UC). Gastroenterology. 110(Suppl):A855.
21. De la Torre B, Fransson J, Scheynius A. 1995 Blood dehydroepiandrosterone sulphate (DHEAS) levels in pemphigoid/pemphigus and psoriasis. Clin Exp Rheumatol. 13:345-348.
22. Yanase T, Fukahori M, Taniguchi S, et al. 1996 Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEA-S) in Alzheimer's disease and in vascular dementia. Endocr J. 43:119-123.
23. Van Vollenhoven RF, Engleman EG, McGuire JL. 1995 Dehydroepiandrosterone in systemic lupus erythematosus: results of a double blind, placebo-controlled, randomized clinical trial. Arthritis Rheum. 38:1826-1831.
24. Nestler JE, Clore JN, Blackard WG. 1992 Dehydroepiandrosterone: the "missing link" between hyperinsulinemia and atherosclerosis? FASEB J. 6:3073-3075.
25. Barrett-Connor E, Khaw KT, Yen SS. 1986 A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 315:1519-1524.
26. Gordon GB, Bush DE, Weisman HF. 1988 Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimai injury. J Clin Invest. 82:712-720.
27. Alexandersen P, Haarbo J, Christiansen C. 1996 The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis. 125:1-13.
28. Williams PJ, Jones RHV, Rademacher TW. 1997 Reduction in the incidence and severity of collagen-induced arthritis in DBA/1 mice using exogenous dehydroepiandrosterone. Arthritis Rheum. 40:907-911.
29. Rasmussen KR, Martin EG, Healey MC. 1993 Effects of dehydroepiandrosterone in immunosuppressed rats infected with Cryptosporidium parvum. J Parasitol. 79:364-370.
30. Loria RM, Inge TH, Cook SS, Szakal AK, Regelson W. 1988 Protection against acute lethal viral infections with the native steroid dehydroepiandrosterone (DHEA). J Med Virol. 26:301-314.
31. Daynes RA, Dudley DJ, BA Araneo. 1990 Regulation of murine lymphokine production in vivo. II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells. Eur J Immunol. 20:793-802.
32. Araghi-Niknam M, Liang B, Zhang Z, Ardestani SK, Watson RR. 1997 Modulation of immune dysfunction during murine leukaemia retrovirus infection of old mice by dehydroepiandrosterone sulphate (DHEAS). Immunology. 90:344-349.
33. Padgett DA, Loria RM. 1994 In vitro potentiation of lymphocyte activation by dehyroepiandrosterone, andrastenediol, and androstenetriol. J Immunol. 153:1544-1552.
34. Pahlavani MA, Harris MD. 1995 Effect of dehydroepiandrosterone on mitogen-induced lymphocyte proliferation and cytokine production in young and old F344 rats. Immunol Lett. 47:9-14.
35. Bulloch K, McEwen BS, Diwa A, Baird S. 1995 Relationship between dehydroepiandrosterone and calcitonin gene-related peptide in the mouse thymus. Am J Physiol. 268:E168-E173.
36. Blauer KL, Poth M, Rogers WM, Bernton EW. 1991 Dehydroepiandrosterone antagonizes the suppressive effects of dexamethasone on lymphocyte proliferation. Endocrinology. 129:3174-3179.
37. Risdon G, Moore TA, Kumar V, Bennett M. 1991 Inhibition of murine natural killer cell differentiation by dehydroepiandrosterone. Blood. 78:2387-2391.
38. Danenberg HD, Alpert G, Lustig S, Ben-Nathan D. 1992 Dehydroepiandrosterone protects mice from endotoxin toxicity and reduces tumor necrosis factor production. Antimicrob Agents Chemother. 36:2275-2279.
39. Di Santo E, Sironi M, Mennini T, et al. 1996 A glucocorticoid receptor-independent mechanism for neurosteroid inhibition of tumor necrosis factor production. Eur J Pharmacol. 299:179-186.
40. Suzuki H, Yasukawa K, Saito T, et al. 1993 Serum soluble interleukin-6 receptor in MRL lpr mice is elevated with age and mediates the interleukin-6 signal. Eur J Immunol. 23:1078-1082.
41. Belmin J, Bernard C, Corman B, Merval R, Esposito B, Tedgui A. 1995 Increased production of tumor necrosis factor and interleukin-6 by arterial wall of aged rats. Am J Physiol. 268:H2288-H2293.
42. Hager K, Machein U, Krieger S, Platt D, Seefried G, Bauer J. 1994 Interleukin-6 and selected plasma proteins in healthy persons of different ages. Neurobiol Aging. 15:771-772.
43. Wie J, Xu H, Davies JL, Hemmings GP. 1992 Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci. 51:1953-1956.
44. Ganong WF. 1989 Review of medical physiology. East Norwalk: Appleton and Lange.
45. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. 1991 Elevated levels of endogenous IL-6 in systemic lupus erythematosus. J Immunol. 147:117-123.